Outcomes of established pregnancies treated with antepartum rituximab for severe maternal disease
| Country . | Age, y . | Indication . | Narrative . | Pregnancy outcome . |
|---|---|---|---|---|
| Germany | 35 | Burkitt lymphoma | Treatment with rituximab began after week 16 | Healthy female |
| Germany4 | 29 | NHL | Rituximab, vincristine, doxorubicin, and prednisone administered during the second trimester | Healthy female, 35 wk |
| France | 20 | NHL | Rituximab was administered at 28 wk of pregnancy | Female, 32 wk; leukopenia and anemia |
| France | 34 | Hodgkin disease | Rituximab administered at week 33 | Healthy, 39 wk |
| France | 41 | Autoimmune hemolytic anemia | Rituximab administered between weeks 7 and 10 | Healthy female, 38 wk |
| France | 45 | ITP | Rituximab administered at week 33 for profound thrombocytopenia | Male, 35 wk; lymphopenia* |
| Australia | B-cell lymphoma | Rituximab, cyclophosphamide, doxorubicin, and vincristine administered during the third trimester | Premature male, 35 wk | |
| France | 28 | NHL | Rituximab and CHOP were administered at 18 wk | Healthy baby |
| United States | 26 | TTP | Rituximab, prednisone, and labetalol administered during the second trimester | Premature infant, 31 wk |
| France | 19 | TTP | RItuximab administered during the second trimester | Premature male, 36 wk; CMV hepatitis |
| Switzerland | 35 | Burkitt lymphoma | Rituximab and CHOP administered at week 16 | Healthy female, 41 wk; B-cell depletion with Rituxan in cord blood |
| United Kingdom | 21 | TTP | Rituximab administered during the third trimester | Healthy male |
| United States | 28 | NHL | Rituximab + CHOP administered at week 21 | Healthy female, 33 wk; preeclampsia |
| United States | 19 | Burkitt lymphoma | Rituximab and multiagent chemotherapy were administered at 13 wk | Healthy female, 39 wk |
| United Kingdom | 28 | ITP | Rituximab administered in seventh month | Female, 39 wk; neonatal thrombocytopenia with cerebral hemorrhage |
| United States | 27 | ITP | Rituximab administered during week 34 | Baby |
| Sweden | 38 | NHL | Rituximab administered in third trimester | Healthy female |
| Netherlands | 36 | ITP | Rituximab administered weeks 30-34 | Healthy female, 38 wk; Rituxan in cord blood |
| Canada | 35 | ITP | Rituximab administered in sixth month (after amniocentesis diagnosed Turner syndrome) | Delivery at 36 wk; absent B cells in neonate |
| Switzerland | 31 | NHL | Rituximab + CHOP administered at 15 wk of gestation | Female, 33 wk; low B cells at birth |
| France | 30 | ITP | Rituximab administered during the fifth month | Ongoing |
| Country . | Age, y . | Indication . | Narrative . | Pregnancy outcome . |
|---|---|---|---|---|
| Germany | 35 | Burkitt lymphoma | Treatment with rituximab began after week 16 | Healthy female |
| Germany4 | 29 | NHL | Rituximab, vincristine, doxorubicin, and prednisone administered during the second trimester | Healthy female, 35 wk |
| France | 20 | NHL | Rituximab was administered at 28 wk of pregnancy | Female, 32 wk; leukopenia and anemia |
| France | 34 | Hodgkin disease | Rituximab administered at week 33 | Healthy, 39 wk |
| France | 41 | Autoimmune hemolytic anemia | Rituximab administered between weeks 7 and 10 | Healthy female, 38 wk |
| France | 45 | ITP | Rituximab administered at week 33 for profound thrombocytopenia | Male, 35 wk; lymphopenia* |
| Australia | B-cell lymphoma | Rituximab, cyclophosphamide, doxorubicin, and vincristine administered during the third trimester | Premature male, 35 wk | |
| France | 28 | NHL | Rituximab and CHOP were administered at 18 wk | Healthy baby |
| United States | 26 | TTP | Rituximab, prednisone, and labetalol administered during the second trimester | Premature infant, 31 wk |
| France | 19 | TTP | RItuximab administered during the second trimester | Premature male, 36 wk; CMV hepatitis |
| Switzerland | 35 | Burkitt lymphoma | Rituximab and CHOP administered at week 16 | Healthy female, 41 wk; B-cell depletion with Rituxan in cord blood |
| United Kingdom | 21 | TTP | Rituximab administered during the third trimester | Healthy male |
| United States | 28 | NHL | Rituximab + CHOP administered at week 21 | Healthy female, 33 wk; preeclampsia |
| United States | 19 | Burkitt lymphoma | Rituximab and multiagent chemotherapy were administered at 13 wk | Healthy female, 39 wk |
| United Kingdom | 28 | ITP | Rituximab administered in seventh month | Female, 39 wk; neonatal thrombocytopenia with cerebral hemorrhage |
| United States | 27 | ITP | Rituximab administered during week 34 | Baby |
| Sweden | 38 | NHL | Rituximab administered in third trimester | Healthy female |
| Netherlands | 36 | ITP | Rituximab administered weeks 30-34 | Healthy female, 38 wk; Rituxan in cord blood |
| Canada | 35 | ITP | Rituximab administered in sixth month (after amniocentesis diagnosed Turner syndrome) | Delivery at 36 wk; absent B cells in neonate |
| Switzerland | 31 | NHL | Rituximab + CHOP administered at 15 wk of gestation | Female, 33 wk; low B cells at birth |
| France | 30 | ITP | Rituximab administered during the fifth month | Ongoing |
NHL indicates non-Hodgkin lymphoma; ITP, idiopathic thrombocytopenia purpura; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; TTP, thrombotic thrombocytopenia; and CMV, cytomegalovirus.